Diets for Sick Children

PEDIATRICS ◽  
1966 ◽  
Vol 37 (4) ◽  
pp. 705-705
Author(s):  
J. W. GERRARD
Keyword(s):  
Celiac Disease ◽  
Dietary Treatment ◽  
Pediatric Diseases ◽  
Sick Children

It is axiomatic that many pediatric diseases require dietary treatment, sometimes as the sole form of therapy, for example, in celiac disease and phenylketonuria, and sometimes as an adjunct, as in nephrosis and diabetes. Diets for Sick Children gives very practical and careful guidance in the preparation of diets for all such children. The proprietary foods referred to in the text are those commonly available on the English market; its usefulness is, therefore, limited on this side of the Atlantic, but it should prove a useful addition to any pediatric dietetic department, and is recommended on this account.

Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: Correlation with dietary treatment

2009 ◽  
Vol 70 (6) ◽  
pp. 430-435 ◽  
Author(s):  
Giovanni Frisullo ◽  
Viviana Nociti ◽  
Raffaele Iorio ◽  
Agata Katia Patanella ◽  
Alessandro Marti ◽  
...  
Keyword(s):  
T Cells ◽  
Celiac Disease ◽  
Peripheral Blood ◽  
Dietary Treatment

Gut Transit in Celiac Disease: Delay of Small Bowel Transit and Acceleration after Dietary Treatment

2004 ◽  
Vol 99 (12) ◽  
pp. 2429-2436 ◽  
Author(s):  
Riadh Sadik ◽  
Hasse Abrahamsson ◽  
Anders Kilander ◽  
Per-Ove Stotzer
Keyword(s):  
Celiac Disease ◽  
Small Bowel ◽  
Dietary Treatment ◽  
Small Bowel Transit

scholarly journals The importance of genetic factors in the development of celiac disease in children of the Uzbek population

2020 ◽  
pp. 22-27
Author(s):  
Z.M. Abdujabarova ◽  
◽  
A.T. Kamilova ◽  
Keyword(s):  
Celiac Disease ◽  
Relative Risk ◽  
Medical Center ◽  
Class Ii ◽  
Control Group ◽  
Population Genetic Study ◽  
Hla Dq ◽  
Sick Children ◽  
Hla Dqa1 ◽  
Relationship Of

The results of genetic studies have proven the relationship of celiac disease with class II genes of the major histocompatibility complex (HLA), in particular with the DQ locus. The presence of specific alleles at the HLA-DQ locus is necessary, but insufficient, for the realization of the disease phenotype. In Uzbekistan, the distribution of HLA markers in children with celiac disease has not been studied and these studies are required. Purpose — to establish the peculiarities of the distribution of HLA II class celiac disease alleles in children in the Uzbek population. Materials and methods. We examined 54 children with celiac disease of the Uzbek population, who were registered and receiving inpatient treatment at the Republican Specialized Scientific and Practical Medical Center of Pediatrics. The age of the examined children was from 1 to 14 years old, the average age was 7.3±1.9 years. The control group consisted of 109 unrelated Uzbeks without immune diseases. Molecular typing of HLA II class genes was determined by DNA chain reaction polymerase. Results. As a result of gene typing, 48 (88.8%) out of 54 investigated had DQ2 and DQ8 haplotypes associated with celiac disease. Haplotypes with only DQ2 and DQ8 were found in 19 (39.5%) and 7 (14.5%), respectively. DQ2 from 48 children was found in 18 (37.5%) children in the trans-position, in 2 (4,1%) — as two copies of DQ2 dimers, and in 1 (2%) case in combination with DQ8. Only in one case (2%) was DQ8 found as two copies of DQ8 dimers. The frequency of occurrence of the HLA-DRB1*07 and *13 alleles was significantly higher than in the control group. The maximum value of the relative risk and the criterion of reliability are noted in the DQA1*0501 allele, i.e. it is positively associated with celiac disease (χ2=7.28, RR=2.03). Significance criterion and relative risk were observed in sick children with DQB1*0201 (χ2=6.74, RR=1.97) associated with celiac disease. The number of haplotype (DQA1*0501-DQB1*0201) was 36 (75%). Conclusions. A specific predisposition to celiac disease in children of the Uzbek population is associated with the genes HLA-DQA1*0501, HLA-DQB1*0201, HLA-DRB1*07 and *13. Alleles such as DRB1*15, DQA1*0102, DQB1*0303 and *0502, have a protective effect in the development of celiac disease in children of the Uzbek population. A high frequency of carriage of the DRB1*13 — HLA-DQА1*0501 and DQB1*0201 (DQ2 type) haplotype in Uzbeks (75%) was found, which requires a more thorough population genetic study of the Uzbek population for the HLA II class DRB1-DQA1-DQB1 genes. The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of these Institutes. The informed consent of the patient was obtained for conducting the studies. No conflict of interest was declared by the authors. Key words: celiac disease, children, genetics, HLA class II.

scholarly journals New Insights into Non-Dietary Treatment in Celiac Disease: Emerging Therapeutic Options

Nutrients ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 2146
Author(s):  
Verónica Segura ◽  
Ángela Ruiz-Carnicer ◽  
Carolina Sousa ◽  
María de Lourdes Moreno
Keyword(s):  
Celiac Disease ◽  
Dietary Treatment ◽  
Immunological Tolerance ◽  
Phase Iii ◽  
Intestinal Lumen ◽  
Intestinal Damage ◽  
Gluten Free ◽  
Response Modulation ◽  
Immune Response Modulation

To date, the only treatment for celiac disease (CD) consists of a strict lifelong gluten-free diet (GFD), which has numerous limitations in patients with CD. For this reason, dietary transgressions are frequent, implying intestinal damage and possible long-term complications. There is an unquestionable need for non-dietary alternatives to avoid damage by involuntary contamination or voluntary dietary transgressions. In recent years, different therapies and treatments for CD have been developed and studied based on the degradation of gluten in the intestinal lumen, regulation of the immune response, modulation of intestinal permeability, and induction of immunological tolerance. In this review, therapeutic lines for CD are evaluated with special emphasis on phase III and II clinical trials, some of which have promising results.

scholarly journals Daily Life Restrictions are Common and Associated with Health Concerns and Dietary Challenges in Adult Celiac Disease Patients Diagnosed in Childhood

Nutrients ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1718 ◽  
Author(s):  
Heini Leinonen ◽  
Laura Kivelä ◽  
Marja-Leena Lähdeaho ◽  
Heini Huhtala ◽  
Katri Kaukinen ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Rating Scale ◽  
Daily Life ◽  
Young Patients ◽  
Dietary Treatment ◽  
Well Being ◽  
Diagnostic Features ◽  
Health Concerns ◽  
Gastrointestinal Symptom Rating Scale ◽  
Adult Celiac Disease

The prevalence and associated factors of daily life restrictions due to a gluten-free diet in adult celiac disease patients diagnosed in childhood are poorly known. We investigated these issues by collecting the medical data of 955 pediatric patients and sending questionnaires evaluating various health outcomes to the 559 patients who had reached adulthood. Of the 231 respondents, 46% reported everyday life restrictions caused by dietary treatment. Compared with those without restrictions, they more often had anemia at diagnosis (37% vs. 22%, p = 0.014), but the groups were comparable in other diagnostic features. In adulthood, patients with restrictions reported more overall symptoms (32% vs. 17%, p = 0.006), although the symptoms measured with the Gastrointestinal Symptom Rating Scale questionnaire were comparable. Despite strict dietary adherence in both groups, the experience of restrictions was associated with dietary challenges (34% vs. 9%, p < 0.001), health concerns (22% vs. 13%, p = 0.050), and lower vitality scores in the Psychological General Well-Being questionnaire. The groups did not differ in their current age, socioeconomic status, family history of celiac disease, general health or health-related lifestyle, the presence of co-morbidities, or regular follow up. Our results encourage healthcare professionals to discuss the possible health concerns and dietary challenges with patients to avoid unnecessary daily life restrictions, especially when young patients start to take responsibility for their treatment.

scholarly journals Regression of conjunctival tumor during dietary treatment of celiac disease

2010 ◽  
Vol 58 (5) ◽  
pp. 433 ◽  
Author(s):  
Samuray Tuncer ◽  
Baris Yeniad ◽  
Gonul Peksayar
Keyword(s):  
Celiac Disease ◽  
Dietary Treatment ◽  
Conjunctival Tumor

scholarly journals Up-Regulation of Specific Bioactive Lipids in Celiac Disease

Nutrients ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 2271
Author(s):  
Rafael Martín-Masot ◽  
Jose Daniel Galo-Licona ◽  
Natàlia Mota-Martorell ◽  
Joaquim Sol ◽  
Mariona Jové ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Phosphatidic Acid ◽  
Metabolic Networks ◽  
Dietary Treatment ◽  
Bioactive Lipids ◽  
Metabolic Defects ◽  
Molecular Features ◽  
Plasma Metabolome ◽  
Lipid Species ◽  
A Minor

Celiac disease (CD) is an autoimmune enteropathy linked to alterations of metabolism. Currently, limited untargeted metabolomic studies evaluating differences in the plasma metabolome of CD subjects have been documented. We engage in a metabolomic study that analyzes plasma metabolome in 17 children with CD treated with a gluten-free diet and 17 healthy control siblings in order to recognize potential changes in metabolic networks. Our data demonstrates the persistence of metabolic defects in CD subjects in spite of the dietary treatment, affecting a minor but significant fraction (around 4%, 209 out of 4893 molecular features) of the analyzed plasma metabolome. The affected molecular species are mainly, but not exclusively, lipid species with a particular affectation of steroids and derivatives (indicating an adrenal gland affectation), glycerophospholipids (to highlight phosphatidic acid), glycerolipids (with a special affectation of diacylglycerols), and fatty acyls (eicosanoids). Our findings are suggestive of an activation of the diacylglycerol-phosphatidic acid signaling pathway in CD that may potentially have detrimental effects via activation of several targets including protein kinases such as mTOR, which could be the basis of the morbidity and mortality connected with untreated CD. However, more studies are necessary to validate this idea regarding CD.

scholarly journals Adherence to dietary treatment and clinical factors associated with anti-transglutaminase antibodies in celiac disease during the follow-up

Heliyon ◽  
2021 ◽  
Vol 7 (4) ◽  
pp. e06642
Author(s):  
Marta Miró ◽  
Manuel Alonso-Garrido ◽  
Manuel Lozano ◽  
Juanjo Peiró ◽  
Lara Manyes
Keyword(s):  
Celiac Disease ◽  
Dietary Treatment ◽  
Clinical Factors ◽  
Factors Associated

Novel Treatments for Celiac Disease: Glutenases and Beyond

2015 ◽  
Vol 33 (2) ◽  
pp. 277-281 ◽  
Author(s):  
Katri Kaukinen ◽  
Katri Lindfors
Keyword(s):  
Celiac Disease ◽  
Dietary Treatment ◽  
Gluten Free Diet ◽  
Intestinal Lumen ◽  
Gluten Free ◽  
Novel Treatments ◽  
Gluten Peptides ◽  
Downstream Effects ◽  
Complete Digestion ◽  
Novel Drug

Currently, the only effective treatment for celiac disease is a strict lifelong gluten-free diet. However, gluten-free dieting is restrictive, difficult to maintain and nutritionally less than optimal. The improved knowledge on celiac disease pathogenesis has enabled researchers to suggest alternative strategies to treat the disorder. The drug development poses a challenge as any novel drug for celiac disease should be simultaneously effective and as safe as the gluten-free diet. The rationale behind enzyme supplementation therapy as a future treatment option for celiac patients lies in the fact that gluten is only poorly digested by gastrointestinal proteases. Due to incomplete degradation in the gastrointestinal tract, fairly long gluten peptides enter the small-intestinal lumen and come into contact with the mucosal epithelium, and in celiac disease patients this encounter launches deleterious downstream effects. Enzyme supplement therapy using either bacterial or fungal endopeptidases or proteases from germinating cereals has been proposed to promote complete digestion of prolamins and destroy disease-inducing gluten peptides. A major advantage of these glutenases is that they work in the lumen of the small intestine and do not themselves take part in the immunological cascade of events in the lamina propria, thus being unlikely to cause harmful side effects to the host. Studies to test this rationale, e.g. with Aspergillus niger prolyl endoprotease and a combination enzyme product ALV003, are already ongoing. The development of a novel medication for celiac disease is still in its early days, and thus the conventional dietary treatment will hold its place for the time being.

Sign in / Sign up

Export Citation Format

Share Document